SCHEMBL24645309

SCHEMBL24645309

COC(=O)[C@H]1CC(C)CN1C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PEPD P12955 1/20 0.47
MMP2 P08253 2/20 0.43
ANPEP P15144 2/20 0.43
CYP3A4 P08684 3/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
CYP2C19 P33261 1/20 0.42
NR1H2 P55055 2/20 0.41
NR1H3 Q13133 1/20 0.41
PTPN1 P18031 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.37
MAPT P10636 2/20 0.36
P2RX3 P56373 1/20 0.36
PDE4B Q07343 1/20 0.36
HTRA1 Q92743 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18462537 1.00 PEPD (0.47) PEPDMMP2ANPEPCYP3A4CYP1A2
SCHEMBL114925 1.00 PEPD (0.47) PEPDMMP2ANPEPCYP3A4CYP1A2
SCHEMBL18589421 1.00 PEPD (0.47) PEPDMMP2ANPEPCYP3A4CYP1A2
SCHEMBL16357004 1.00 PEPD (0.47) PEPDMMP2ANPEPCYP3A4CYP1A2
SCHEMBL882756 1.00 PEPD (0.47) PEPDMMP2ANPEPCYP3A4CYP1A2
SCHEMBL14205631 1.00 PEPD (0.47) PEPDMMP2ANPEPCYP3A4CYP1A2
SCHEMBL4703753 0.90 CHRM2 (0.42) PEPDCYP3A4CYP1A2POLBCYP2C19
SCHEMBL27017249 0.90 CHRM2 (0.42) PEPDCYP3A4CYP1A2POLBCYP2C19
SCHEMBL20006799 0.88 MMP2 (0.41) PEPDMMP2ANPEPCYP3A4CYP1A2
SCHEMBL1412106 0.88 CYP3A4 (0.53) PEPDMMP2ANPEPCYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676929-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 Dark Blue Therapeutics Ltd (GB) 2026-01-14 EP disclosed
EP-4638447-A1 IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS Dark Blue Therapeutics Ltd (GB) 2025-10-29 EP disclosed
WO-2024188906-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 DARK BLUE THERAPEUTICS LTD (GB) 2024-09-19 WO disclosed
EP-4428134-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 Dark Blue Therapeutics Ltd (GB) 2024-09-11 EP disclosed
WO-2024133560-A1 IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS DARK BLUE THERAPEUTICS LTD (GB) 2024-06-27 WO disclosed
US-20220305011-A1 FACTOR XIIA INHIBITORS UNIVERSITY OF LEEDS (GB) 2022-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220305011-A1 FACTOR XIIA INHIBITORS F11, F13B, F12 PEPD 59/4885MMP2 68/4885ANPEP 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.